MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-01-2026
China Pharma Holdings Market Cap 2011-2026 | CPHI
As of May 09, 2026 China Pharma Holdings has a market cap of $ 2.27 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap China Pharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.75 M | 454 K | 1.25 M | 368 K | 2.21 M | 30.9 M | 18.3 M | 12.6 M | 14.8 M | 10.9 M | 6.1 M | 13.1 M | 18.7 M | 10.9 M | 33 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33 M | 368 K | 11.8 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 4.68 | 9.09 % | $ 65.8 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
3.63 B | $ 2.54 | -1.17 % | $ 1.31 B |  Canada |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Organogenesis Holdings
ORGO
|
337 M | $ 2.37 | -6.32 % | $ 300 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 23.15 | -2.07 % | $ 1.07 B | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
3.38 B | $ 5.75 | 0.35 % | $ 2.1 B | Canada |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 1.11 | -1.77 % | $ 119 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 1.2 | 1.69 % | $ 1.49 M | USA |
 |
Harrow Health
HROW
|
1.93 B | $ 38.23 | -2.1 % | $ 1.41 B | USA |
 |
Solid Biosciences
SLDB
|
623 M | $ 7.27 | 2.83 % | $ 636 M | USA |
 |
Aurora Cannabis
ACB
|
915 M | $ 3.41 | -0.58 % | $ 86.3 M | Canada |
 |
Tilray
TLRY
|
1.19 B | $ 5.56 | -1.77 % | $ 3.44 B | Canada |
 |
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
151 M | $ 1.36 | -1.45 % | $ 130 M | Canada |
 |
Evolus
EOLS
|
271 M | $ 6.36 | -0.47 % | $ 410 M | USA |
 |
Sundial Growers
SNDL
|
889 K | $ 1.44 | -1.03 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
108 M | $ 2.24 | -1.75 % | $ 302 M | USA |
 |
Emergent BioSolutions
EBS
|
139 M | $ 9.5 | 4.05 % | $ 486 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
1.68 M | $ 0.84 | -3.45 % | $ 3.62 M | USA |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
75.4 M | $ 22.5 | 0.58 % | $ 144 M | USA |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 7.32 | -1.48 % | $ 289 M | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 0.92 | -4.35 % | $ 45.9 M | USA |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 17.17 | -1.27 % | $ 20 B | USA |
 |
Zomedica Corp.
ZOM
|
137 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
33.8 M | $ 0.83 | 6.76 % | $ 29.9 M | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
23 M | $ 1.98 | -1.49 % | $ 22.9 M | USA |